ImmunoBrain's Anti-PD-L1 Antibody Cuts Alzheimer's Damage Biomarkers in Phase Ib
IBC-Ab002, a transient PD-1/PD-L1 checkpoint blocker, cut neurogranin 23.1% and tTau 12.4% at 48 weeks in 40 early Alzheimer's patients, with no ARIA or hemorrhage reported.
TAG K-5091 · 930 words on the filing

Summary of findings
- Phase Ib (NCT05551741): neurogranin −23.1%, tTau −12.4%, pTau181 −11.0% at 30 mg/kg versus pooled placebo at 48 weeks.
- Forty patients, five dose cohorts (1–30 mg/kg), four doses at 3-month intervals, one-year follow-up; no ARIA or brain hemorrhage.
- Antibody half-life approximately four days; Phase IIb paperwork submitted to FDA; company is raising funds.
- Francis Collins, NIH director 2009–2021, joined ImmunoBrain's board last month.
- Field context: 98% Phase II/III failure rate in 2022 study; 567 trials 2010–2026 criticized for repeated ineffective mechanisms.
Neurogranin, an Alzheimer's biomarker tied to cognitive performance, fell 23.1% at 48 weeks in early Alzheimer's patients treated with ImmunoBrain's anti-PD-L1 antibody IBC-Ab002. The Phase Ib first-in-human study (NCT05551741), published in Nature Medicine and presented at AAIC in London, July 12–15, enrolled 40 patients across five ascending dose cohorts from 1 to 30 mg/kg, dosed four times at 3-month intervals with one-year follow-up. Primary endpoints were safety and tolerability.
What did the data show?
At the 30 mg/kg dose versus pooled placebo, exploratory CSF analyses showed tTau down 12.4% and pTau181 down 11.0%, with intraindividual consistency across all three markers. VAMP2, a pre-synaptic biomarker, trended similarly to neurogranin, with strong correlation between individual responses. No brain hemorrhaging or ARIA occurred. The antibody's half-life ran approximately four days across all dose cohorts.
"The biomarkers show an encouraging result, mainly the Neurogranin that is Alzheimer's characteristic marker and prediction of cognitive performance," said Michal Schwartz, PhD, ImmunoBrain's scientific co-founder and chief scientific officer, and one of three corresponding authors on the Nature Medicine paper. She added the obvious caveat: "We cannot speak about statistical significance because of the small number of patients and the short duration of the follow-up, but it was beyond our expectation to see from such a small study."
How does the mechanism differ from amyloid approaches?
IBC-Ab002 is engineered for transient, intermittent blockade of the PD-1/PD-L1 pathway in chronic neurodegenerative disease. The blockade triggers homing of immune-repairing monocytes and regulatory T cells that clear senescent microglia and resolve inflammation. The molecule combines high-affinity PD-L1 binding with Fc effector silencing and reduced FcRn binding, designed to eliminate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
"It's not just a disease of only accumulation of toxic protein," Schwartz told GEN. "Once symptoms are seen, the disease progression is driven not only by the amyloid plaque, but an additional major factor, local inflammation." She called inflammation "not the primary cause, it's not the trigger, but definitely a catalyzer." Schwartz is also a professor of neuroimmunology at the Weizmann Institute of Science in Rehovot, Israel.
A companion paper in Nature Neuroscience in September, with Schwartz as corresponding author, showed impaired bone marrow myelopoiesis — the production of monocyte-derived macrophages and their recruitment to the brain — in both a mouse model and Alzheimer's patients. The cause, she said, is chronic type I interferon elevation: "If this type 1 interferon is chronically produced, it becomes an enemy of the bone marrow. And we found the same situation in mice and in humans." The finding echoes her lab's 2014 Science paper linking brain aging to type I interferon.
Because the strategy does not target a specific proteinopathy, Schwartz and colleagues wrote, "it has broader applicability across other chronic neurodegenerative conditions in which neuroinflammation contributes to disease progression."
What comes next?
ImmunoBrain has submitted Phase IIb paperwork to the FDA and is raising funds. The planned study would follow participants for two years. "We are aiming to do a big study, very rigorous, with a very ambitious endpoint, so if successful, as it seems based on the Phase Ib, it may speed up approval of this drug and may be considered as a pivotal study," Schwartz said.
Last month the 11-year-old company added Francis Collins, MD, PhD — NIH director from 2009 to 2021, the longest-tenured presidentially appointed director — to its board. "The ImmunoBrain approach is, for me, a completely compelling and novel approach," Collins said, calling it "potentially groundbreaking." His enthusiasm carries a built-in question mark: "The question is: can we show that this intervention changes the course of the illness? It will take a big push to answer that. It's going to cost a lot of money."
Why the field context matters
The backdrop remains brutal. The Cleveland Clinic's widely quoted 99.6% candidate failure rate barely improved in a 2022 study showing 98% failure across Phase II and III. An August analysis by Michael A.S. Guth, PhD, JD, covering 567 Phase II/III Alzheimer's trials from 2010 to 2026, blamed "structural and institutional forces that sustained investment in repeatedly ineffective mechanisms of action" and pointed to "deeper problems of disease definition, intervention timing, and endpoint validity."
Approved products show the limits of the current model. Biogen and Eisai's Aduhelm never won CMS coverage and was dropped in 2024. Leqembi, the first disease-modifying therapy with full FDA approval, gained subcutaneous starter and maintenance doses — the July starter marketed as Leqembi Iqlik — and posted $202 million in Q3 global sales, up 67% from $121 million a year earlier, including $68 million in Biogen's Alzheimer's collaboration revenue. Lilly's Kisunla won approval in 2024 as the first plaque-targeting therapy supporting treatment cessation once plaques clear.
Phase III pipelines remain largely amyloid-centric: Roche/Genentech's trontinemab (TRONTIER1 and TRONTIER2, primary completion February 2028; PrevenTRON estimated 2032) and Lilly's remternetug (TRAILRUNNER-ALZ 3, data expected 2029). At CTAD in Boston this week, AriBio's oral PDE5 inhibitor AR1001 showed a statistically significant −0.44-point CDR-SB difference at Week 52 (p=0.0266, 31% slowing) — but the full 1,535-participant population missed significance at −0.11 points (p=0.4015). GWAS data pointing to more than 100 risk signals, with microglia and innate immunity dominant, remain largely unexploited therapeutically. ImmunoBrain is betting that gap is the opportunity.
via alzres.biomedcentral.com (Original)
More from Rebecca Stone
Show full bio
Staff writer covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.
10 articles
Linked filings
- V-5496
- K-8685
- T-8005
- C-4460
- V-7932